QuidelOrtho AI Stock Analysis
QuidelOrtho (0A55) AI Stock Analysis
QuidelOrtho
(LSE:0A55)
No summary available
QuidelOrtho (0A55) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $736.90M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -2.0
- Beta (1Y)
- -0.13
- Revenue Growth
- -4.64%
- EPS Growth
- 68.20%
- Country
- UK
- Employees
- 6,500
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Specialties
QuidelOrtho Business Overview & Revenue Model
Company Description
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemi...
QuidelOrtho Earnings Call Summary
The call reflected a mixed but cautiously constructive outlook. The company reported significant revenue, respiratory, China, margin, and leverage pressures, narrowed its guidance, and expects restructuring charges in the fourth quarter. However, management emphasized resilient low to mid-single-digit growth in the core labs and immunohematology businesses, improved cash flow, disciplined capital spending, more than $80 million of incremental annual savings, and continued investment in VITROS 450 and NULEXA. The underlying business remains challenged by China and respiratory trends, but management presented concrete actions to improve profitability, cash generation, and deleveraging.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
QuidelOrtho narrowed full year revenue guidance from $2.52 billion to $2.6 billion to a range of $2.52 billion to $2.54 billion, and now expects full year 2026 adjusted EBITDA of $540 million to $545 million and adjusted earnings per share of $0.65 to $0.70; labs and immunohematology are expected to deliver low to mid-single-digit growth in 2026, excluding China, while guidance incorporates a cautious fourth quarter respiratory assumption based on trends through the end of the third quarter. China is expected to represent approximately 8% of total company revenue in 2026 and approximately 4% to 5% in 2027, with continued destocking throughout the remainder of 2026 and the majority of the pricing impact expected in 2027. The cost transformation and enterprise restructuring program is expected to deliver more than $80 million of annual savings in 2027, starting in the fourth quarter this year and ramping throughout 2027 with slightly more weight in the second half than the first half; the company expects to record approximately $30 million to $35 million of onetime restructuring charges in the fourth quarter, with the majority of the related cash outflow occurring in the fourth quarter of 2026.
QuidelOrtho Risk Analysis
QuidelOrtho disclosed 48 risk factors in its most recent earnings report. QuidelOrtho reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksQuidelOrtho Peers Comparison
Overall Rating
MLAB67Neutral
MDAI46Neutral
LAB44Neutral
BEAT43Neutral
TRIB38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 67Neutral | $781.31M | 117.81 | 3.52% | 0.46% | 2.47% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $41.84M | -3.95 | 100.93% | ― | -38.62% | 55.03% | |
| 44Neutral | $279.27M | -6.44 | -7.54% | ― | -34.46% | 47.75% | |
| 43Neutral | $25.04M | -0.94 | -402.72% | ― | ― | 38.22% | |
| 38Underperform | $3.93M | -0.13 | 48.72% | ― | -13.28% | 39.65% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0A55 | Quidelortho Corporation | 13.56 | -29.94 | -68.83% | |
| LAB | Standard Biotools Inc | 0.71 | -0.50 | -41.57% | |
| MLAB | Mesa Laboratories | 139.01 | 67.85 | 95.35% | |
| TRIB | Trinity Biotech | 6.10 | -18.47 | -75.17% | |
| MDAI | Spectral Ai, Inc. Class A | 1.30 | -0.14 | -9.72% | |
| BEAT | Heartbeam, Inc. | 0.40 | -1.15 | -74.35% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
